Livzon Pharmaceutical Group (LP6) Ratios
Livzon Pharmaceutical Group Ratios
DE:LP6's free cash flow for Q3 2026 was $648.25M. For the 2026 fiscal year, DE:LP6's free cash flow was decreased by $-130.22M and operating cash flow was $778.47M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.23 | 2.15 | 2.14 | 2.30 | 2.12 |
| Quick Ratio | 2.02 | 1.89 | 1.88 | 2.02 | 1.88 |
| Cash Ratio | 1.29 | 1.42 | 1.40 | 1.41 | 1.32 |
| Solvency Ratio | 0.31 | 0.28 | 0.27 | 0.26 | 0.28 |
| Operating Cash Flow Ratio | 0.43 | 0.39 | 0.40 | 0.37 | 0.27 |
| Short-Term Operating Cash Flow Coverage | 1.01 | 1.21 | 1.75 | 1.71 | 0.93 |
| Net Current Asset Value | $ 7.92B | $ 6.87B | $ 6.99B | $ 7.06B | $ 6.61B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.16 | 0.16 | 0.14 | 0.15 | 0.12 |
| Debt-to-Equity Ratio | 0.28 | 0.28 | 0.25 | 0.26 | 0.21 |
| Debt-to-Capital Ratio | 0.22 | 0.22 | 0.20 | 0.21 | 0.17 |
| Long-Term Debt-to-Capital Ratio | 0.05 | 0.10 | 0.10 | 0.12 | 0.05 |
| Financial Leverage Ratio | 1.73 | 1.76 | 1.78 | 1.79 | 1.72 |
| Debt Service Coverage Ratio | 0.84 | 1.17 | 1.45 | 1.57 | 1.17 |
| Interest Coverage Ratio | 48.99 | 32.10 | 23.66 | 24.10 | 26.99 |
| Debt to Market Cap | 0.17 | 0.16 | 0.17 | 0.17 | 0.12 |
| Interest Debt Per Share | 4.37 | 4.37 | 3.85 | 3.98 | 2.97 |
| Net Debt to EBITDA | -1.76 | -1.99 | -2.36 | -2.21 | -2.33 |
| Profitability Margins | |||||
| Gross Profit Margin | 65.90% | 65.45% | 61.61% | 64.68% | 64.75% |
| EBIT Margin | 21.85% | 24.51% | 19.99% | 19.23% | 19.31% |
| EBITDA Margin | 25.75% | 29.38% | 26.75% | 24.39% | 23.00% |
| Operating Profit Margin | 24.51% | 24.08% | 19.43% | 18.61% | 18.79% |
| Pretax Profit Margin | 23.81% | 23.76% | 19.17% | 18.45% | 18.62% |
| Net Profit Margin | 16.83% | 17.45% | 15.72% | 15.12% | 14.72% |
| Continuous Operations Profit Margin | 20.06% | 19.51% | 15.27% | 15.48% | 16.18% |
| Net Income Per EBT | 70.69% | 73.45% | 81.99% | 81.93% | 79.07% |
| EBT Per EBIT | 97.15% | 98.66% | 98.66% | 99.15% | 99.06% |
| Return on Assets (ROA) | 8.43% | 8.43% | 7.80% | 7.68% | 7.94% |
| Return on Equity (ROE) | 14.56% | 14.87% | 13.91% | 13.76% | 13.66% |
| Return on Capital Employed (ROCE) | 17.56% | 16.90% | 14.24% | 13.46% | 14.68% |
| Return on Invested Capital (ROIC) | 12.50% | 12.11% | 10.22% | 10.33% | 11.27% |
| Return on Tangible Assets | 8.78% | 8.69% | 7.98% | 7.98% | 8.28% |
| Earnings Yield | 8.84% | 8.66% | 9.58% | 8.82% | 8.19% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.44 | 3.60 | 3.48 | 3.13 | 3.61 |
| Payables Turnover | 7.69 | 2.58 | 2.88 | 2.40 | 2.34 |
| Inventory Turnover | 2.62 | 2.04 | 2.32 | 2.18 | 2.56 |
| Fixed Asset Turnover | 2.75 | 2.60 | 2.72 | 2.75 | 2.85 |
| Asset Turnover | 0.50 | 0.48 | 0.50 | 0.51 | 0.54 |
| Working Capital Turnover Ratio | 1.36 | 1.31 | 1.32 | 1.46 | 1.48 |
| Cash Conversion Cycle | 197.82 | 138.46 | 135.74 | 131.73 | 87.88 |
| Days of Sales Outstanding | 106.21 | 101.46 | 104.98 | 116.73 | 101.11 |
| Days of Inventory Outstanding | 139.07 | 178.66 | 157.60 | 167.34 | 142.74 |
| Days of Payables Outstanding | 47.46 | 141.67 | 126.84 | 152.34 | 155.96 |
| Operating Cycle | 245.28 | 280.13 | 262.58 | 284.07 | 243.84 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 3.47 | 3.24 | 3.49 | 2.97 | 2.04 |
| Free Cash Flow Per Share | 2.84 | 2.62 | 2.61 | 1.96 | 0.63 |
| Dividend Paid and CapEx Coverage Ratio | 2.04 | 1.56 | 1.35 | 1.10 | 0.74 |
| Capital Expenditure Coverage Ratio | 5.54 | 5.22 | 3.96 | 2.95 | 1.45 |
| Operating Cash Flow Coverage Ratio | 0.80 | 0.76 | 0.93 | 0.77 | 0.71 |
| Operating Cash Flow to Sales Ratio | 0.26 | 0.25 | 0.26 | 0.22 | 0.16 |
| Free Cash Flow Yield | 11.09% | 10.12% | 11.90% | 8.47% | 2.74% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 11.28 | 11.55 | 10.44 | 11.34 | 12.21 |
| Price-to-Sales (P/S) Ratio | 1.90 | 2.02 | 1.64 | 1.71 | 1.80 |
| Price-to-Book (P/B) Ratio | 1.65 | 1.72 | 1.45 | 1.56 | 1.67 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 9.02 | 9.88 | 8.40 | 11.81 | 36.56 |
| Price-to-Operating Cash Flow Ratio | 7.39 | 7.99 | 6.28 | 7.81 | 11.40 |
| Price-to-Earnings Growth (PEG) Ratio | 8.43 | 1.73 | 3.55 | 1.54 | 3.19 |
| Enterprise Value Multiple | 5.63 | 4.87 | 3.78 | 4.82 | 5.49 |
| Enterprise Value | 17.42B | 16.92B | 12.56B | 14.85B | 15.24B |
| EV to EBITDA | 5.63 | 4.87 | 3.78 | 4.82 | 5.49 |
| EV to Sales | 1.45 | 1.43 | 1.01 | 1.18 | 1.26 |
| EV to Free Cash Flow | 6.86 | 7.02 | 5.17 | 8.11 | 25.69 |
| EV to Operating Cash Flow | 5.62 | 5.68 | 3.86 | 5.36 | 8.01 |
| Tangible Book Value Per Share | 16.61 | 15.39 | 14.97 | 15.00 | 14.31 |
| Shareholders’ Equity Per Share | 15.56 | 15.07 | 15.09 | 14.86 | 13.92 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.16 | 0.18 | 0.20 | 0.16 | 0.13 |
| Revenue Per Share | 13.46 | 12.84 | 13.36 | 13.52 | 12.91 |
| Net Income Per Share | 2.27 | 2.24 | 2.10 | 2.04 | 1.90 |
| Tax Burden | 0.71 | 0.73 | 0.82 | 0.82 | 0.79 |
| Interest Burden | 1.09 | 0.97 | 0.96 | 0.96 | 0.96 |
| Research & Development to Revenue | 0.07 | 0.09 | 0.11 | 0.11 | 0.09 |
| SG&A to Revenue | 0.27 | 0.25 | 0.05 | 0.05 | 0.02 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.57 | 1.29 | 1.71 | 1.42 | 0.97 |
Currency in CNY